E Durvalumab (Genetical Recombination) (500mg 10mL／vial) 200 vials
F Benralizumab (Genetical Recombination) (30mg 1mL／syringe) 100 syringes
G Olaparib (150mg 56tablets／case) 200 cases
H Palivizumab (Genetical Recombination) (100mg 1mL／vial) 400 vials
I Asfotase alfa (Genetical Recombination) (40mg 1mL／vial) 100 vials
J Asfotase alfa (Genetical Recombination) (80mg 0.8mL／vial) 200 vials
K Eculizumab (Genetical Recombination) (300mg 30mL／vial) 100 vials
L Ravulizumab (Genetical Recombination) (300mg 30mL／vial) 100 vials
M Adalimumab (Genetical Recombination) (40mg 0.4mL／syringe) 1,000 syringes
N Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30-tablets／vial) 200 vials
O Eftrenonacog Alfa (Genetical Recombination) (3,000IU ／ vial (with solution)) 90 vials
P Imiglucerase (Genetical Recombination) (400units／vial) 100 vials
Q Dupilumab (Genetical Recombination) (300mg 2mL／syringe) 700 syringes
R Agalsidase beta (Genetical Recombination) (5mg／vial) 300 vials
S Agalsidase beta (Genetical Recombination) (35mg／vial) 100 vials
T Lenalidomide Hydrate (5mg 40capsules／case) 100 cases
U Cetuximab (Genetical Recombination) (100mg 20mL／vial) 1,800 vials
V Ustekinumab (Genetical Recombination) (45mg 0.5mL／syringe) 200 syringes
W Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL／syringe) 500 syringes
X Aflibercept (Genetical Recombination) (2mg 0.05mL／vial) 500 vials
Y Nivolumab (Genetical Recombination) (240mg 24mL／vial) 700 vials
Z Tazobactam Piperacillin Hydrate (4.5g 10vials／case) 2,200 cases
AA Paclitaxel (100mg／vial) 700 vials
AB Palonosetron hydrochloride (0.75mg 50mL 5bags／case) 600 cases
AC Denosumab (Genetical Recombination) (120mg 1.7mL／vial) 1,000 vials
AD Tocilizumab (Genetical Recombination) (200mg 10mL／vial) 1,500 vials
AE Tocilizumab (Genetical Recombination) (162mg 0.9mL／kit) 2,100 kits
AF Bevacizumab (Genetical Recombination) (100mg 4mL／vial) 1,700 vials
AG Bevacizumab (Genetical Recombination) (400mg 16mL／vial) 1,600 vials
AH Atezolizumab (Genetical Recombination) (1200mg 20mL／vial) 100 vials
AI Pertuzumab (Genetical Recombination) (420mg 14mL／vial) 400 vials
AJ Trastuzumab (Genetical Recombination) (150mg／vial (with solution)) 900 vials
AK Infliximab (Genetical Recombination) (100mg／vial) 3,300 vials
AL Pemetrexed Sodium Hydrate (100mg／vial) 800 vials
AM Pemetrexed Sodium Hydrate (500mg／vial) 300 vials
AN Ramucirumab (Genetical Recombination) (500mg 10mL／vial) 90 vials
AO Glatiramer Acetate (20mg 1mL 7syringe／case) 1,200 cases
AP Freeze-dried polyethylene glycol treated human normal immunoglobulin (5g／vial (with soluation)) 1,200 vials

(4) Delivery period : From 1 April, 2021 through 31 March, 2022

(5) Delivery place : Niigata University Medical and Dental Hospital

(6) Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :

A not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,

B have the Grade A or Grade B qualification during fiscal 2021 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,

C prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,

D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,

E meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,

F not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.

(7) Time limit of tender : 17 : 15　12 March, 2021

(8) Contact point for the notice : Yukiyo Aoyama, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951―8520 Japan, TEL 025―227―2430

(9) Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

入札公告

次のとおり一般競争入札に付します。
令和３年１月18日
分任契約責任者
国立大学法人富山大学
医薬系事務部長　佐藤　　修
◎調達機関番号　415　◎所在地番号　16
○第 22 号

1　調達内容
(1)　品目分類番号　4
(2)　購入等件名及び数量
A　ヌシネルセンナトリウム（12mg５ml／１瓶）　五瓶
B　サトラリズマブ（遺伝子組換え）(120mg １ml／１筒)　15筒
(3)　調達件名の特質等　入札説明書による。
(4)　納入期間　令和３年４月１日から令和４年６月30日
(5)　納入場所　国立大学法人富山大学附属病院
(6)　入札方法　上記１(2)の件名ごとにそれぞれ入札に付する。入札金額は、上記１(2)の件名ごとにそれぞれの単価を記載すること。なお、落札決定に当たっては、入札書に記載された金額に当該金額の10パーセントに相当する額を加算した金額をもって落札価格とするので、入札者は、消費税及び地方消費税に係る課税事業者であるか免税事業者であるかを問わず、見積もった契約金額の110分の100に相当する金額を入札書に記載すること。

2　競争参加資格
(1)　国立大学法人富山大学契約規則第５条及び第６条の規定に該当しない者であること。なお、未成年者、被保佐人又は被補助人であって、契約締結のために必要な同意を得ている者は、同条中、特別の理由がある場合に該当する。
(2)　入札者の競争参加資格　国の競争参加資格（全省庁統一資格）において令和３年度(平成33年度)に東海・北陸地域の「物品の販売」のA、B又はC等級に格付けされている者であること。
なお、当該競争参加資格については、令和２年３月31日付け号外政府調達第58号の官報の競争参加者の資格に関する公示の別表に掲げる申請受付窓口において随時受け付けている。